Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Alfresa Holdings is Japan's largest pharmaceutical and medical device wholesaler, distributing prescription drugs, OTC medications, and medical equipment to hospitals, clinics, and pharmacies across Japan. The company operates a nationwide logistics network serving approximately 150,000 healthcare facilities, functioning as the critical intermediary between pharmaceutical manufacturers and healthcare providers in Japan's highly regulated, universal healthcare system.
Alfresa operates on razor-thin wholesale margins (7.2% gross margin) typical of pharmaceutical distribution, earning spreads between manufacturer prices and reimbursement rates set by Japan's National Health Insurance system. Profitability depends on operational efficiency, inventory turnover (estimated 12-15x annually), and scale advantages in logistics. The company leverages its dominant market position (estimated 30-35% market share) to negotiate volume rebates from manufacturers while maintaining essential distribution infrastructure that smaller competitors cannot replicate. Revenue is largely non-discretionary, tied to Japan's aging demographics and chronic disease prevalence rather than economic cycles.
Japanese government drug pricing revisions (biennial NHI reimbursement rate cuts typically 2-8%)
Generic drug penetration rates in Japan (currently ~80% by volume, ~45% by value vs 90%+ in US)
Hospital consolidation trends and group purchasing organization dynamics
Pharmaceutical manufacturer inventory management and direct-to-pharmacy initiatives
Yen exchange rate movements affecting imported drug costs and margins
Japan's fiscal pressures driving accelerated drug price cuts - government targeting 1.5-2.0 trillion yen in annual healthcare savings through 2030, with wholesalers absorbing margin compression
Pharmaceutical manufacturer disintermediation through direct distribution models and digital ordering platforms, bypassing traditional wholesalers
Declining Japanese population (projected -16% by 2050) eventually reducing absolute prescription volumes despite aging demographics
Intense competition from Medipal Holdings and Suzuken in a consolidating three-player oligopoly, limiting pricing power
Hospital group purchasing organizations leveraging scale to demand lower prices and value-added services without margin compensation
Negative $14.5B free cash flow driven by $20.1B capex appears anomalous - likely reflects major logistics automation investment or acquisition, creating near-term cash strain
Working capital intensity exposes company to inventory obsolescence risk from drug recalls or formulary changes
low - Pharmaceutical distribution is highly defensive with minimal GDP correlation. Prescription drug demand is driven by demographics (Japan's 29% elderly population) and chronic disease prevalence, not discretionary spending. However, elective procedures and diagnostic equipment sales show modest cyclicality during severe recessions.
Low direct impact as Debt/Equity is only 0.06, minimizing financing cost sensitivity. However, rising Japanese government bond yields could pressure healthcare budget allocations and accelerate drug price cuts. The company's working capital-intensive model (high receivables/inventory) benefits marginally from low rates but impact is modest given minimal leverage.
Minimal - customers are primarily hospitals and pharmacies with government-backed reimbursement, resulting in low bad debt risk. Trade credit extended to customers is standard practice but default rates are negligible given Japan's universal healthcare payment system.
value - The stock trades at 0.2x sales and 1.0x book value, attracting deep value investors seeking defensive exposure to Japan's healthcare sector. Low growth (3.6% revenue), minimal volatility, and essential infrastructure characteristics appeal to conservative, income-focused portfolios despite modest 5.1% ROE. The flat recent returns (0% across all periods) suggest limited momentum interest.
low - Pharmaceutical distribution exhibits utility-like stability with beta likely 0.5-0.7 to Japanese equity markets. Revenue visibility is high given non-discretionary demand, though margin volatility exists around government pricing decisions.
